8-K: Upstream Bio Reports Positive Phase 2 Trial Enrollment and Financial Results for 2024

Upstream Bio announces completion of Phase 2 clinical trial enrollment for verekitug in CRSwNP and reports financial results for Q4 and full year 2024, highlighting a strong cash position extending through 2027.

Summary

• Upstream Bio reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company completed enrollment in its Phase 2 clinical trial of verekitug for chronic rhinosinusitis with nasal polyps (CRSwNP) in January 2025, with top-line data expected in the second half of 2025.
• Upstream Bio completed an upsized IPO in October 2024, raising approximately $293 million in gross proceeds.
• As of December 31, 2024, Upstream Bio had $470.5 million in cash, cash equivalents, and short-term investments, expected to fund operations through 2027.
• Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for the same period in 2023.
• General and administrative expenses were $5.2 million for the quarter ended December 31, 2024, compared to $3.2 million for the same period in 2023.
• Net loss was $21.2 million for the quarter ended December 31, 2024, compared to a net loss of $11.8 million for the same period in 2023.
• The company expects to dose the first patient in its COPD program in the second half of 2025 and report top-line data from its ongoing Phase 2 clinical trial in severe asthma in the second half of 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful IPO, strong cash position, and progress in clinical trials, although increased expenses and net losses temper the overall outlook.

Positives

• The successful completion of enrollment in the Phase 2 clinical trial for CRSwNP is a positive milestone.
• The upsized IPO provides substantial funding to support planned operations through 2027.
• The strong cash position of $470.5 million provides financial stability.
• Advancement of verekitug into Phase 2 trials for severe asthma and planned initiation of development in COPD are positive steps.

Negatives

• The net loss of $21.2 million for the quarter ended December 31, 2024, is higher than the net loss of $11.8 million for the same period in 2023.
• Increased research and development expenses and general and administrative expenses contributed to the increased net loss.

Risks

• The company's ability to advance verekitug through clinical development and obtain regulatory approval is subject to risks and uncertainties.
• Clinical trial results may differ materially from expectations.
• The company's dependence on third parties to conduct clinical trials and manufacture verekitug poses a risk.
• The company's financial condition and need for additional funds to complete development activities and commercialize verekitug are risks.
• Regulatory developments and approval processes of the FDA and comparable foreign regulatory authorities pose risks.

Future Outlook

Upstream Bio expects to report top-line data from the Phase 2 clinical trial of verekitug in CRSwNP in the second half of 2025, dose the first patient in its COPD program in the second half of 2025, and report top-line data from its Phase 2 clinical trial in severe asthma in the second half of 2026; the company believes it has sufficient capital to fund planned operations through 2027.

Management Comments

• We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical trial of verekitug in patients with CRSwNP in January 2025, said Rand Sutherland, MD, Chief Executive Officer of Upstream.
• We expect to report top-line data from this trial in the second half of 2025, enabling regulatory discussions and preparations for a Phase 3 program in CRSwNP, said Rand Sutherland, MD, Chief Executive Officer of Upstream.
• We have also made significant progress developing verekitug in severe asthma and COPD, Dr. Sutherland continued.
• Our recently completed initial public offering has provided us with sufficient capital to fund our planned operations through 2027, supporting our strategy of leveraging verekitug's unique mechanism of action to improve treatment options for patients living with severe inflammatory diseases.

Industry Context

Upstream Bio is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, positioning itself in a competitive market with significant unmet needs; the development of verekitug, targeting the TSLP receptor, aims to provide a novel approach compared to existing treatments.

Comparison to Industry Standards

• Upstream Bio's focus on TSLP inhibition aligns with a growing interest in targeting upstream drivers of inflammation, similar to how Amgen and AstraZeneca's Tezspire also targets TSLP, though Tezspire targets the TSLP ligand rather than the receptor.
• The $293 million raised in the IPO is a substantial amount, providing a strong financial foundation compared to other clinical-stage biotech companies.
• The company's cash runway through 2027 is competitive, allowing for focused execution on clinical programs.
• The use of nasal polyp score (NPS) as a primary endpoint in the CRSwNP trial is consistent with industry standards and regulatory expectations, as seen in trials for Dupixent and other biologics.

Management Changes

Related Party Transactions

• Collaboration revenue from related party was $613,000 for the three months ended December 31, 2024, and $2.37 million for the year ended December 31, 2024.

Stakeholder Impact

• Shareholders benefit from the successful IPO and extended cash runway.
• Patients with severe respiratory disorders may benefit from the development of verekitug.
• Employees are impacted by changes in personnel-related expenses and management team additions.

Next Steps

• Report top-line data from the Phase 2 clinical trial of verekitug in CRSwNP in the second half of 2025.
• Initiate dosing of the first patient in the COPD program in the second half of 2025.
• Report top-line data from the Phase 2 clinical trial in severe asthma in the second half of 2026.
• Participate in upcoming investor conferences.

Key Dates